Drug Developement

Drug Development Use Cases

PRIMABS-Dx enables rational, biomarker-driven oncology drug development across multiple therapeutic contexts.
 
xx

Patient Stratification

Identify priming patterns that predict response to venetoclax and MCL-1–directed combinations in AML and MM. Enrich clinical trial populations for higher response rates.
 
DD

Pharmacodynamic Readouts

Measure ex vivo treatment-induced shift scores to validate mechanism of action and optimize dosing schedules in early-phase trials.
 
ZZ

Rational Combination Design

Quantify how metabolic, stress-kinase, and cell-cycle agents converge on apoptosis. Guide selection of doublets and triplets with synergistic mechanisms.
 
 

Dynamic shifts in BCL-2 Family PPIs Direct Combination Treatments

The PRIMABs measurements of drug induced shifts in priming can provide utility in predicting patient response.

Drug displacement of Bim changes cancer dependency

The PRIMABS measurements of drug induced shifts in priming from one anti-apoptotic protein to another reveals a cancer cell survival adaptation. This understanding can guide treatment decisions.

zz

Here the displacement of BIM from BCL-2 and corresponding binding to MCL-1 is illustrated. This shift is seen to be a cause of venetoclax resistance. Detection of this shift instructs treatment that impacts MCL-1 Bim Complex

Dynamic PRIMABS™ Readouts Detect Priming Shifts

The data shows that PRIMABS detect such a shift in priming status following BH3-mimetic treatment (priming changes from Bcl-xL to MCL-1) that correlates to specific drug sensitivity..

Cell line samples were measured with PRIMABS staining and flow detection before and after treatment .